Integrin α6β4 signals through DNA damage response pathway to sensitize breast cancer cells to cisplatin

Integrin α6β4 is highly expressed in triple negative breast cancer (TNBC) and drives its most aggressive traits; however, its impact on chemotherapeutic efficacy remains untested. We found that integrin α6β4 signaling promoted sensitivity to cisplatin and carboplatin but not to other chemotherapies...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Min, Marrs, Brock, Qi, Lei, Knifley, Teresa, Weiss, Heidi L., D’Orazio, John A., O’Connor, Kathleen L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9686853/
https://www.ncbi.nlm.nih.gov/pubmed/36439467
http://dx.doi.org/10.3389/fonc.2022.1043538

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9686853/
https://www.ncbi.nlm.nih.gov/pubmed/36439467
http://dx.doi.org/10.3389/fonc.2022.1043538

Ejemplares similares